From Australia
Suven Life Sciences has secured a product patent from Australia corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
